At a glance
ClinicalIndex Comparison RecordN/ACompleted· 26 enrolled
Drug / intervention
VSS-Rx1 OPM vs Commercial iDesign Treatmentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Study to Evaluate the Feasibility of a New Treatment Algorithm for Wavefront-Guided Lasik Correction of Myopic Refractive Errors
In Brief
A clinical study evaluating VSS-Rx1 OPM vs Commercial iDesign Treatment for Myopia and Astigmatism. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The purpose of this clinical trial is to demonstrate that treatments generated by an investigational algorithm reduces spherical aberration compared to currently available iDesign treatments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyopia, Astigmatism
CountriesColombia
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedNov 2013
Primary CompletionJul 2014
TodayJul 2026
First PostedNov 20, 2013
Enrollment StartNov 1, 2013
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.6 years ago
Interventions
VSS-Rx1 OPM vs Commercial iDesign Treatmentdevice
Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile vs VSS-Rx1 OPM (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration).